Danaher Corporation (DHR) Stock Analysis
Latest ClaritX AI analysis ·
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongs
| Metric | Value |
|---|---|
| Price | $214.06 |
| Market cap | $150.5B |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
| ClaritX AI score | 86/100 |
| Price/Book | 2.87 |
| Dividend yield | 0.71% |
| Beta | 0.81 |
AI verdict
Danaher Corporation (DHR) remains a premier, defense-oriented compounder within the global healthcare sector, seamlessly merging absolute balance sheet safety with an irrefutable institutional accumulation phase. Currently trading at $214.06, the stock is positioned exactly 11.84% below its 52-week high of $242.80. This strategic distance from its annual peak, combined with a highly balanced RSI of 61.92 and a successful reclamation of its 20-day SMA, implies the stock has completed a healthy, technical digestion and resumed its broader macro uptrend. Concurrently, Danaher's heavily insulated volatility profile is mathematically verified by an ultra-low beta of 0.808, significantly mitigating downside tail-risk and isolating the asset from systemic macroeconomic turbulence as it prepares for its October 21 earnings call. The underlying fundamental thesis is virtually unassailable, driven by an elite 15.95% net profit margin and a staggering 65.73x interest coverage ratio that nullifies credit risk. The explosive catalyst remains the unprecedented internal and external capital accumulation. During Q3 2026, corporate insiders aggressively acquired over 3.58 million shares, echoed by a nearly billion-dollar external purchase from Bank of America. With CEO Julie Sawyer Montgomery now officially at the helm, Danaher perfectly aligns massive smart-money inflows with structural operational superiority, solidifying its status as an elite long-term total-return vehicle. Rating 86/100
What this score has been worth
ClaritX scores DHR 86 out of 100 (snapshot 2026-10-05).
Every ClaritX analysis is scored first and judged only on what the stock did afterwards. Across the 203 analyses that scored in the 85-89 band, the average forward return was +1.7% with a 52% win rate, -3.7pp against the S&P 500. That is a measured tendency across many names, not a forecast for DHR — roughly 48% of stocks in this band still lost money.
The full band-by-band table, including the bands that lost, is on the AI Rank Report; the live strategy arms behind it are on the AI Track Record, losses published.